SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bafna Pharma spurts on launching RARICAP injection in domestic market

20 Nov 2013 Evaluate

Bafna Pharmaceuticals is currently trading at Rs. 26.45, up by 1 point or 3.93% from its previous closing of Rs. 25.45 on the BSE.

The scrip opened at Rs 26.00 and has touched a high and low of Rs 26.00 and Rs 25.65 respectively. So far 17000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 51.70 on 07-Jan-2013 and a 52 week low of Rs 17.90 on 29-Jul-2013.

Last one week high and low of the scrip stood at Rs 27.50 and Rs 24.00 respectively. The current market cap of the company is Rs 48.23 crore.

The promoters holding in the company stood at 30.87% while Non-Institutionsheld 69.13% of the stake.

Bafna Pharmaceuticals, a Chennai-based Pharma company, has launched RARICAP in injection form as RARICAP S in domestic market. This is another product in women wellness segment for Iron Deficiency Anaemia during Pregnancy and also for Anaemia in Chronic Kidney Disease.

Bafna Pharmaceutical is a Chennai-based Pharma company engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non-Betalactum. The company has 173 products registered in UK, Sri Lanka, Nepal, Ukraine, Ghana, Ethiopia, Philippines, Kryghistan, Georgia, Honduras, Colombia, Uzbekhistan, Vietnam and Nigeria.

Bafna Pharma Share Price

133.00 0.95 (0.72%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×